| Similar Articles |
|---|
 |
The Motley Fool
September 6, 2006
Brian Lawler |
Catalyst for ZymoGenetics? Trial results for a drug that controls bleeding include a favorable comparison with a similar product. Investors, take note.   |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool
May 16, 2007
Mike Havrilla |
ZymoGenetics Is Poised to Stop Bleeding With shares of ZymoGenetics currently trading near three-year lows, now may be a good time to pick some up. |
The Motley Fool
December 31, 2010
Brian Orelli |
2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions. |
The Motley Fool
September 30, 2010
Brian Orelli |
Bristol-Myers' Delayed Steal ZymoGenetics price tag looks more reasonable. |
The Motley Fool
January 30, 2009
Brian Orelli |
Mark Your Calendars: The Race Is On! In the last couple of weeks, both Schering-Plough and Vertex Pharmaceuticals have announced that their phase 3 hepatitis C drugs trials have finished enrolling patients. |
The Motley Fool
January 28, 2010
Brian Orelli |
How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward. |
The Motley Fool
September 8, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
January 14, 2009
Brian Orelli |
ZymoGenetics, the Pharmaceutical Zombie ZymoGenetics deal with Bristol-Myers may bring the drug developer stumbling back from the dead. |
The Motley Fool
March 8, 2010
Brian Orelli |
Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting. |
The Motley Fool
July 30, 2010
Brian Orelli |
A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs. |
The Motley Fool
September 7, 2010
Luke Timmerman |
ZymoGenetics, Seattle Biotech Pioneer, Acquired by Bristol-Myers for $885 Million The two companies have gotten to know each other quite well since January 2009, when Bristol agreed to pay as much as $1.1 billion for the right to co-develop and co-market a drug for hepatitis C. |
The Motley Fool
October 8, 2010
Luke Timmerman |
Bristol-Myers Almost Ready to Seal the Deal With ZymoGenetics ZymoGenetics, one of the driving forces of Seattle biotech the past 30 years, is about to become a thing of the past. |
The Motley Fool
January 18, 2008
Brian Orelli |
The Battle of the Thrombins ZymoGenetics announces that its recombinant thrombin product, Recothrom, was given a thumbs-up by the FDA. |
The Motley Fool
August 23, 2007
Brian Orelli |
Can't Stop the Bleeding From a Paper Cut ZymoGenetics' rThrombin product is delayed. With a 9% drop in stock price, it looks like investors are overreacting. |
The Motley Fool
May 1, 2007
Mike Havrilla |
Heads Up, Biotech Investors Big news is in the offing for these companies. Pozen... Progenics... Zymogenetics... etc. |
The Motley Fool
November 5, 2008
Brian Orelli |
ZymoGenetics Leads With Its Chin It says a lot about ZymoGenetics' quarter that management decided to open its conference call talking about its hepatitis C drug still in trials, rather than the sales results of its blood-clotting agent, Recothrom. |
The Motley Fool
May 15, 2007
Brian Lawler |
King Fights for Its Empire King Pharmaceuticals announces another good quarter of financial results. Investors should expect more product acquisitions in the coming years. |
The Motley Fool
August 28, 2007
Brian Orelli |
FDA Makes Cows Happy The FDA approves Omrix's human-derived thrombin, which replaces a version made from cattle. |
The Motley Fool
August 21, 2009
Brian Orelli |
ZymoGenetics Goes in for the Kill ZymoGenetics went on the offensive, asking the Food and Drug Administration to pull competitor King Pharmaceuticals' Thrombin-JMI off the market. |
